Item 7.01. Regulation FD Disclosure.

On January 10, 2022, 23andMe Holding Co. (the "Company") issued a press release announcing that the Company received FDA clearance for a direct-to-consumer genetic health risk report on a hereditary prostate cancer marker. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.

The information in this report furnished pursuant to Item 7.01, including Exhibit 99.1 attached hereto, shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. It may only be incorporated by reference in another filing under the Exchange Act or the Securities Act of 1933, as amended, if such subsequent filing specifically references the information furnished pursuant to Item 7.01 of this report.

Item 9.01. Financial Statements and Exhibits.





(d) Exhibits.



Exhibit No.         Description of Exhibit

99.1                  23andMe Holding Co. Press Release, dated January 10,
                    2022
104                 Cover Page Interactive Data File - the cover page
                    interactive data file does not appear in the Interactive
                    Data File because its XBRL tags are embedded within the
                    Inline XBRL document

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses